Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer
- PMID: 3382761
- DOI: 10.1007/BF01807555
Relevance of cell kinetics to hormonal response of receptor-positive advanced breast cancer
Abstract
The relationship between cell kinetics and hormonal status and the relevance of the cell kinetic variable on success of hormone-therapy in estrogen receptor positive (ER+) breast tumors were analyzed in patients with advanced disease. Cell kinetics were evaluated as in vitro 3H-thymidine labeling index (LI), and estrogen receptor (ER) and progesterone receptor (PgR) with the dextran-coated charcoal technique. The analyses performed on primary tumor or soft tissue metastases from 52 patients showed a general association between the presence of hormone receptors and low proliferative activity, or the absence of receptors and high proliferative activity (ER and L.I.: p greater than 0.05; PgR and L.I.: p = 0.05). However, hormonal status and cell kinetic status were unrelated in about 40% of the cases. Clinical response to additive hormonotherapy was analyzed in relation to pretreatment LI in 29 patients with ER+ tumors. Time to reach maximum response was significantly longer in slow than in fast proliferating tumors, but complete remission was reached in 88% of slow proliferating tumors compared to only 46% of fast proliferating tumors. These preliminary results show that ER+ fast proliferating tumors largely escape hormonal control, and if confirmed on larger series, could identify cell kinetics as an important tool to select patients who will benefit from hormonal treatment.
Similar articles
-
Tumor-proliferative activity, progesterone receptor status, estrogen receptor level, and clinical outcome of estrogen receptor-positive advanced breast cancer.Cancer Res. 1990 May 15;50(10):2958-62. Cancer Res. 1990. PMID: 2334898
-
Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.J Clin Oncol. 1992 Aug;10(8):1284-91. doi: 10.1200/JCO.1992.10.8.1284. J Clin Oncol. 1992. PMID: 1634918
-
Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer.Breast Cancer Res Treat. 2016 Nov;160(2):313-322. doi: 10.1007/s10549-016-4007-5. Epub 2016 Oct 8. Breast Cancer Res Treat. 2016. PMID: 27722840 Free PMC article.
-
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status.Ann Oncol. 2006 May;17(5):818-26. doi: 10.1093/annonc/mdl016. Epub 2006 Feb 23. Ann Oncol. 2006. PMID: 16497822 Clinical Trial.
-
Predictive value of tumor estrogen and progesterone receptor levels in postmenopausal women with advanced breast cancer treated with toremifene.Cancer. 1990 Dec 1;66(11):2264-9. doi: 10.1002/1097-0142(19901201)66:11<2264::aid-cncr2820661103>3.0.co;2-9. Cancer. 1990. PMID: 2147123 Review.
Cited by
-
Needle biopsy accelerates pro-metastatic changes and systemic dissemination in breast cancer: Implications for mortality by surgery delay.Cell Rep Med. 2023 Dec 19;4(12):101330. doi: 10.1016/j.xcrm.2023.101330. Cell Rep Med. 2023. PMID: 38118415 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical
Research Materials